Shane Johnson, MD
Dr. Shane Johnson’s career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech. Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane’s work has been focused on the cannabis and cannabinoid science space, and he has developed a strong working knowledge of clinical opportunities in the sector. He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada’s leading cultivators and producers of premium cannabis products including a patented lozenge. Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar.
Co-Founder, President & CEO
Philip Barr, PhD
As a graduate student, Dr. Phil Barr invented the antiviral compound Brivudine, which was approved for use in Europe. While Director of Molecular Biology at Chiron (now Novartis) and Adjunct Professor of Pharmaceutical Chemistry at UC San Francisco, Phil headed or worked with teams that used engineered yeast to successfully manufacture yeast-derived recombinant human insulin (Novolin, Novo Nordisk) and gamma-interferon (with Lucky Goldstar), the first bio-pharmaceutical approved for use in Asia. He also developed commercial diagnostic antigens for HIV and HCV, and later as Founder, CSO and CEO of Arriva Pharmaceuticals, he spearheaded the development of recombinant human alpha 1-antitrypsin for hereditary emphysema. Phil has significant industrial scale experience with yeast, including ultra-low cost manufacturing of biofuels and specialty chemicals. He has specialized in the field of polyketide production in yeast. Significantly, the cannabinoids are members of the polyketide family of natural products. Notably he also holds over 50 issued patents, and has authored some 200 papers and book chapters in chemistry, yeast molecular biology and genetic engineering. Phil holds a Ph.D. in organic chemistry, has over 30 years of experience in industrial chemistry and molecular biology, and was the primary editor of the first book on commercial yeast genetic engineering.
Co-Founder, Chief Scientific Officer
Charles Marlowe, PhD
While at COR Therapeutics, Millennium Pharmaceuticals, Takeda and Exelixis Inc., Dr. Chuck Marlowe was instrumental in helping drive a number of small molecule therapeutics to entry into later-stage clinical trials and FDA approval. These products include Integrilin and Betrixaban (FDA-approved) , Cromafiban, XL147 and XL765 (Phase II, with Sanofi) and Elinogrel Phase III, with Novartis. Has worked in a number of fields including agricultural chemistry with Dow Chemical, biotechnology with Chiron Corporation (now Novartis Pharmaceuticals), and medicinal chemistry. Most recently Chuck was the Principal of Pharmaceutical Consultants, supplying chemical expertise to startup companies in the pharmaceutical, biotechnology, fermentation and the renewable synthetic biology space. Chuck has authored over 30 publications in leading journals and holds over 25 issued world and US patents. He holds a Ph.D. in organic chemistry from UC Berkeley, and was an NIH Postdoctoral fellow at Stanford University.
Co-Founder, Director of Chemistry
Dave Kent has extensive experience in the capital management and pharmaceutical industries. In his early career at Smith Barney / CITIGROUP his team was responsible for regional corporate finance throughout the Middle East. Later at both Morgan Stanley and Lehman Brothers he managed proprietary funds, private equity partnership and investment opportunities for clients in both Europe and the Middle East from offices in London. He then went on to found Ventec private equity where his focus was on raising funds for emerging growth companies in industries including Biotechnology, Natural Resources and Technology. In 1997 he co-founded Arriva Pharmaceuticals with Phil Barr and served as CFO where he successfully raised seed capital through Series C venture capital. At Arriva he negotiated multiple joint ventures with Prometic Life Science and Baxter Healthcare. Returning to finance, at Fortinbras Asset Management, he helped raise in excess of $1.0billion for a variety of clients. Most recently Dave has served as CEO of both DOR Biopharma and Karuna Biomedical.
VP Corporate Development
Jim Kealey, PhD
Dr. Jim Kealey has an extensive background in biochemistry, molecular biology, enzymology and synthetic biology. He has focused his research efforts using these skills to engineer organisms, including yeast, to produce small molecules, pharmaceuticals, and biofuels. At Intrexon, Jim built and managed a large research team that developed pioneering methods and platforms to convert inexpensive methane into higher value products. His use of a Design-Build-Test-Learn approach allowed him to grow his cross-functional team to 30+ members while rapidly engineering molecules from proof of concept to pilot commercialization scale. In his role as director he served as point person for presenting the team’s work to a variety of outside audiences. Prior to Intrexon, Jim led a number of groups at Amyris whose focus was the rapid engineering and development of S. cerevisiae to produce terpenes for industrial applications – (terpenes are common compounds in cannabis). While as Kosan Biosciences, Jim led groups that focused on the production of polyketides – a class of molecules that include anticancer, antibiotic and cannabinoids. Jim earned a BA in Biochemistry & Molecular Biology of UC Santa Cruz and a PhD in Pharmaceutical Chemistry from UCSF.
VP Research & Development
Chris Meiering, PhD
With a career spanning the scientific and consumer packaged goods industries, including over 20 years of leadership at Zuke’s Performance Pet Nutrition (up through their acquisition by Purina), Dr. Chris Meiering brings a unique skill set to BayMedica. He is a scientist and self-directed business strategist with a history of innovation from concept to shelf and a proven track record bringing products to market. His skills range from information technology, e-commerce, social media, marketing, innovation, product development & formulation, business development, business insights & sales to molecular biology, genetic engineering and virology. With his unique scientific background and experience Chris has the ability to deliver simple solutions to complex problems in a consumer-friendly manner. He has diverse background and experience in corporate environments including: bootstrap startup, organic growth, equity-backed expansion, merger and acquisition, and large cap consumer packaged goods. Chris received a B.S. in Microbiology from the University of Arizona (magna cum laude), his Ph.D. in microbiology, specializing in molecular virology, from the University of Washington, and performed his post-doctoral research as a fellow at Stanford University.
Jianping Sun, PhD
Dr. JP Sun has over 18 years experience in research, including biochemistry, molecular biology, microbiology, and fermentation process development. JP collaborated with Allopartis to engineer a fungal strain for expression of bacteria cellulosic enzymes. At Intrexon, she successfully automated a fungal expression platform and developed a high throughput transformation and screening system. She also successfully engineered Methanotrophs for production of biofuels. Most recently, JP was the Senior Scientist of Rho renewables where she successfully engineered yeast strains for aromatic chemical production and developed fermentation process for improved yield and production. She has authored numerous publications in premier scientific journals and is an inventor on several patents in biotechnology. JP received a PhD in biochemistry and molecular biology from the University of Science and Technology of China and completed her postdoctoral studies at the University of California, Berkeley.
Director of Molecular Biology
Gil Labrucherie brings over 20 years of senior leadership experience in finance, legal and corporate development to the Board. He is currently the CFO of Nektar Therapeutics (NKTR), a $10B publicly traded company, and is also a member of the Board of Directors of Rezolute (RZLT). Prior to serving as CFO of Nektar, Gil was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Gil was an executive at different organizations (E2Open and Alta Vista Company) where he was responsible for global corporate alliances and mergers and acquisitions. Gil began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Gil received his J.D. from University of California Berkeley School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Gil is a member of the State Bar of California and is a Certified Management Accountant.